02:28:28 EDT Mon 27 May 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:TNYA - TENAYA THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
TNYA - Q4.04.15·4.800.54.54+0.184.1260.21,0941,2994.40  4.60  4.238.0914  1.6617:12:30May 1415 min RT 2¢

Recent Trades - Last 10 of 1299
Time ETExPriceChangeVolume
17:12:30Q4.600.242
16:07:37Q4.600.245
16:07:37Q4.600.244
16:01:52Q4.540.181,179
16:01:44Q4.540.18110
16:00:07Q4.540.18800
16:00:07Q4.540.18182
16:00:00Q4.540.18303
16:00:00Q4.540.1856
16:00:00Q4.540.18306

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-14 16:05U:TNYANews ReleaseTenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
2024-05-02 17:00U:TNYANews ReleaseTenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
2024-03-18 16:05U:TNYANews ReleaseTenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2024-03-18 08:30U:TNYANews ReleaseTenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
2024-02-27 16:30U:TNYANews ReleaseTenaya Therapeutics to Participate in Upcoming March Investor Conferences
2024-02-26 08:30U:TNYANews ReleaseTenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications
2024-02-08 08:00U:TNYANews ReleaseTenaya Therapeutics Announces Pricing of Underwritten Offering
2024-01-03 08:30U:TNYANews ReleaseTenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-21 16:30U:TNYANews ReleaseTenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference
2023-11-08 16:05U:TNYANews ReleaseTenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
2023-10-26 08:30U:TNYANews ReleaseTenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
2023-10-09 08:30U:TNYANews ReleaseTenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from ‚  HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure ‚  with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting
2023-10-05 08:30U:TNYANews ReleaseTenaya Therapeutics Doses First Patient in the MyPeak-1 ¢ „ ¢ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
2023-10-02 17:30U:TNYANews ReleaseTenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration
2023-09-21 16:05U:TNYANews ReleaseTenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences
2023-08-31 16:05U:TNYANews ReleaseTenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference
2023-08-09 16:05U:TNYANews ReleaseTenaya Therapeutics Reports Second Quarter 2023 Financial Results and ‚  Provides Business Update
2023-08-02 16:05U:TNYANews ReleaseTenaya Therapeutics to Participate at the 43rd Annual Canaccord Genuity Growth Conference